Quantcast

Latest Alimera Sciences Inc. Stories

2014-06-30 08:29:57

ATLANTA, June 30, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced the positive outcome of the Repeat-Use Procedure for ILUVIEN® for the treatment of chronic diabetic macular edema (DME) in an additional 10 European Union countries. Alimera submitted the application through the Mutual Recognition Procedure...

2014-06-23 08:27:39

ATLANTA, June 23, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to...

2014-05-27 16:25:30

ATLANTA, May 27, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, president and chief executive officer, will present at the Jefferies 2014 Healthcare Conference on Thursday, June 5, 2014 at 1:30 P.M. ET in New York, NY. The presentation will be webcast live and will be available for...

2014-05-08 16:27:04

ILUVIEN® Revenue Up Over 120% Sequentially from Fourth Quarter of 2013 ATLANTA, May 8, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the first quarter ended March 31, 2014. "We achieved solid revenue growth from sales of ILUVIEN during this first quarter of 2014 due to increasing...

2014-05-01 08:34:53

ATLANTA, May 1, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its first quarter of fiscal year 2014 financial results after the market close on Thursday, May 8, 2014. An investor conference call will follow on the same day at 4:30 p.m. ET. The conference call will be hosted by Dan...

2014-04-28 08:30:58

-- Intravitreal corticosteroid implant for treatment of vision impairment associated with diabetic macular oedema MELBOURNE, Australia and ATLANTA, April 28, 2014 /PRNewswire/ -- Australian and New Zealand patients suffering from vision impairment due to a type of diabetes-induced eye disease will have access to a new treatment, following a license deal between Australian biopharmaceutical company Specialised Therapeutics Australia (STA) and Alimera Sciences (NASDAQ: ALIM). The exclusive...

2014-04-28 08:30:56

ATLANTA and MELBOURNE, Australia, April 28, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has signed an exclusive five-year agreement with Specialised Therapeutics Australia (STA) for the distribution in Australia and New Zealand of ILUVIEN®, Alimera's sustained release intravitreal injection for...

2014-04-25 08:27:00

ATLANTA, April 25, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that its United Kingdom subsidiary, Alimera Sciences Limited (Limited), has entered into a Loan and Security Agreement with Hercules Technology Growth Capital, Inc. (NYSE: HTGC) (Hercules) for a term loan in the principal amount of up to $35...

2014-04-14 12:33:11

PDUFA goal date set for September 26, 2014 ATLANTA, April 14, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that its recent resubmission of the New Drug Application (NDA) for ILUVIEN(®) has been acknowledged as received by the U.S. Food and Drug Administration (FDA) as a complete class 2 response to the...

2014-03-27 08:33:35

ATLANTA, March 27, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has resubmitted its New Drug Application for ILUVIEN(®) to the U.S. Food and Drug Administration (FDA). At this time, Alimera awaits the FDA's acceptance of the resubmission and a Prescription Drug User Fee Act (PDUFA) date. Alimera...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related